Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 13.5% in February

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 2,760,000 shares, a decline of 13.5% from the February 13th total of 3,190,000 shares. Based on an average daily volume of 278,600 shares, the days-to-cover ratio is presently 9.9 days. Approximately 11.2% of the company’s stock are sold short.

Krystal Biotech Price Performance

KRYS traded up $0.65 during trading on Wednesday, reaching $189.15. 44,148 shares of the company’s stock were exchanged, compared to its average volume of 283,578. Krystal Biotech has a 1 year low of $141.72 and a 1 year high of $219.34. The company’s fifty day simple moving average is $164.69 and its 200-day simple moving average is $173.58. The stock has a market capitalization of $5.45 billion, a P/E ratio of 62.95 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the business posted $0.30 EPS. The company’s revenue was up 116.4% on a year-over-year basis. Equities analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KRYS. Norges Bank purchased a new stake in shares of Krystal Biotech during the 4th quarter worth about $34,391,000. Soleus Capital Management L.P. boosted its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after purchasing an additional 122,407 shares during the period. State Street Corp grew its holdings in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at approximately $15,989,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KRYS has been the topic of several research analyst reports. Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).